Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2019-05-17

Last Posted Date: 2021-10-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 478

Registration Number: NCT03954834

Locations: 🇮🇳
BSES Municipal General Hsptl, Mumbai, Maharashtra, India
🇯🇵
Meiwa Hospital, Chiyodaku, Tokyo, Japan
🇯🇵
Tokyo Center Clinic, Chuo-ku, Tokyo, Japan

and more 47 locations

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: LY900014
Drug: Insulin Lispro
Drug: Insulin Glargine
Drug: Insulin Degludec

First Posted Date: 2019-05-16

Last Posted Date: 2022-02-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 628

Registration Number: NCT03952143

Locations: 🇨🇳
Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, Cn-21, China
🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Cn-21, China
🇨🇳
Shanghai Putuo District Center Hospital, Shanghai, Cn-31, China

and more 38 locations

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes

Phase 3

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: LY900014
Drug: Insulin Lispro
Drug: Insulin Glargine
Drug: Insulin Degludec

First Posted Date: 2019-05-16

Last Posted Date: 2023-02-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 354

Registration Number: NCT03952130

Locations: 🇦🇷
Centro Médico Viamonte, Caba, Buenos Aires, Argentina
🇦🇷
Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC, Cordoba, Argentina
🇨🇳
Dongguan people's hospital, Dongguan, Guangdong, China

and more 27 locations

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

Phase 3

Active, not recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: Placebo
Drug: Baricitinib
Drug: Topical corticosteroid

First Posted Date: 2019-05-16

Last Posted Date: 2024-12-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 516

Registration Number: NCT03952559

Locations: 🇦🇺
Veracity Clinical Research, Woolloongabba, Queensland, Australia
🇧🇷
Faculdade de Medicina do ABC, Santo André, Sao Paulo, Brazil
🇨🇿
Fakultni Nemocnice v Motol, Praha, Praha 5, Czechia

and more 75 locations

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide
Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2019-05-15

Last Posted Date: 2023-03-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 117

Registration Number: NCT03951753

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
🇩🇪
Profil Mainz GmbH & Co. KG, Mainz, Rheinland-Pfalz, Germany

A Study of the Effects of LY3372689 on the Brain in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3372689
Diagnostic Test: [18F]LSN3316612

First Posted Date: 2019-05-09

Last Posted Date: 2020-04-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 17

Registration Number: NCT03944031

Locations: 🇺🇸
Invicro, Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Phase 4

Completed

Conditions: Generalized Pustular Psoriasis
Erythrodermic Psoriasis

Interventions: Drug: Ixekizumab

First Posted Date: 2019-05-08

Last Posted Date: 2021-08-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 12

Registration Number: NCT03942042

Locations: 🇯🇵
Jikei University School of Medicine, Minato-Ku, Tokyo, Japan
🇯🇵
Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan
🇯🇵
Teikyo University Hospital, Itabashi-ku, Tokyo, Japan

and more 4 locations

A Drug Interaction Study of LY3154207 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3154207 Tablet
Drug: LY3154207 Capsule
Drug: Fluconazole Tablet

First Posted Date: 2019-05-08

Last Posted Date: 2020-01-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 36

Registration Number: NCT03942029

Locations: 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States

A Study of Tirzepatide in Participants With Impaired Liver Function

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: Tirzepatide

First Posted Date: 2019-05-07

Last Posted Date: 2023-03-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 32

Registration Number: NCT03940742

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
New Orleans Center for Clinical Research, New Orleans, Louisiana, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: LY3434172

First Posted Date: 2019-05-03

Last Posted Date: 2021-06-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 10

Registration Number: NCT03936959

Locations: 🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇰🇷
Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of
🇫🇷
Institut Claudius Regaud - IUCT Oncopole, Toulouse cedex 9, France

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy